How we discover new medicines | Research & Development | GlaxoSmithKline

How we discover and develop new medicines

Creating a new medicine is a long and rigorous process, and much of what we investigate never makes it to patients. In our search for new medicines, our primary concern is patient safety.

It can take up to 15 years to progress from a promising idea in the research laboratory to receiving approval from regulators. We might investigate 5,000 or more different chemicals to identify just one that can be tested in humans.

We begin the search for a new medicine by looking into what processes in the body lead to a disease or create the symptoms. This starting point is based on both our own research and broader knowledge within the scientific community.

Developing a new treatment typically goes through seven stages from laboratory to patient:

Research – identifying a new approach to treat a disease or condition

We use the growing understanding of biology to identify ‘targets’. A target is a structure – like an enzyme – in the body that contributes to the development of a disease or its symptoms. It is important initially to know that the target we select is valid, and that it affects the disease process in the way that the science suggests.

Once a target has been identified, the next step is to find chemicals or natural compounds that might inhibit or enhance the target’s activity. Current techniques allow many hundreds of compounds to be screened for that sort of activity very quickly. Compounds that show the sort of effect we want are called 'hits'.

Discovery – developing and investigating compounds that can alter a disease process

Once we have identified our hits, we narrow down the number of possible compounds by further testing, to come up with lead compounds. Our lead compounds may need to be 'improved' - we may modify them using chemistry to enhance different properties. Ideally we look for compounds that:

  • selectively hit the target for the disease processes
  • can be safely absorbed by the body
  • reach the appropriate point in the body to find the target
  • remain in the system long enough to have an effect
  • can be manufactured to produce a stable preparation convenient to use
  • have few side effects

Pre-clinical testing – understanding how a compound works in a system and its effects

At this stage our researchers do more detailed investigation of the lead compounds. By testing with living cells, bacteria or tissue cultures in the lab, or in animals, scientists can build an understanding of how the compounds behave.

If the work has been successful, the development team will have identified a compound to consider testing in humans.

Clinical trials – carrying out tests in humans

Before any trial in humans can start, a plan is developed that defines what the trial would involve. The plan will be carefully considered by an ethical review committee of experienced independent medical and scientific practitioners. This committee has the power to reject or stop a clinical trial at any time.

New medicines must go through three phases of human testing before they can be approved for use. To find out more about these critical phases in the development of a new medicine go to our section on clinical trials.

The safety of those who take part in clinical trials is of paramount importance. All our clinical trials follow the guidelines developed by the International Conference on Harmonisation (ICH), and the World Medical Association Declaration of Helsinki on the Ethical Principles for Medical Research Involving Human Subjects (2008).

Regulatory approval – gaining approval for a new medicine from government regulators

Once a medicine has successfully completed all three phases of clinical trials, the information is submitted to government regulators. This is the formal application to seek approval for the new medicine. The process must be followed in every territory in which we hope to offer the new treatment to doctors and patients.

Based on our research, we suggest to the regulators which patients may find our medicines helpful, but it is the regulators who make the final decisions. Their approval will include details of the diseases or conditions that the medicine has been cleared to treat. Regulators may also require restrictions or warnings to be placed on the use of new medicines.

Only after the regulators have given their approval to a medicine can we make it available to doctors to prescribe to patients.

Supply – manufacturing and shipping the approved medicine so that doctors can prescribe it

The approved new medicine is now manufactured and distributed. Doctors are supplied with the information that will help them in deciding when to prescribe the new treatment.

Go to our section on how we work with doctors to find out:

  • how we advise doctors on the availability of our treatments
  • the ethical standards that we work to in conducting our relationships with medical professionals

Monitoring – continuing to gain understanding from the use of new medicines

As new medicines are used more widely, we build a deeper understanding of their effectiveness in different circumstances. This can mean that our appreciation of a medicine changes over time.

Monitoring is overseen by our Global Safety Board (GSB), which is chaired by our Chief Medical Officer and made up of senior physicians and scientists.  To find out more about how we continue to monitor our new medicines once they are in circulation, go to our section on clinical trials in people.